Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer

Abstract
This study indicates that increased efficacy of immune therapies in ovarian cancer is driven by state changes of NK and small subsets of CD8 T cells into active and cytotoxic states.
Funding Information
  • HHS | NIH | National Cancer Institute (K08CA241093)
  • HHS | NIH | NIH Office of the Director (DP5OD029637)
  • American Association for Cancer Research (2019 AACR-AstraZeneca Ovarian Cancer Research Fellowship (Grant Number 19-40-12-HILL))
  • DOD | United States Army | MEDCOM | Congressionally Directed Medical Research Programs (W81XWH-19-1-0123)
  • Honorable Tina Brozman Foundation (Rising Star Grant)
  • Advanced Medical Research Foundation (N/A)
  • Vincent Memorial Hospital Foundation (N/A)
  • HHS | NIH | National Cancer Institute (R01CA234018)
  • China Scholarship Council (201908610120)
  • DOD | United States Army | MEDCOM | Congressionally Directed Medical Research Programs (W81XWH-19-1-0147)